Hardy Kiera, Chmelo Jakub, Joel Abraham, Navidi Maziar, Fergie Bridget H, Phillips Alexander W
Northern Oesophagogastric Unit, Royal Victoria Infirmary, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK.
Department of Cellular Pathology, Royal Victoria Infirmary, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK.
Langenbecks Arch Surg. 2023 May 9;408(1):184. doi: 10.1007/s00423-023-02927-z.
PURPOSE: Prognosis of oesophageal cancer is primarily based upon the TNM stage of the disease. However, even in those with similar TNM staging, survival can be varied. Additional histopathological factors including venous invasion (VI), lymphatic invasion (LI) and perineural invasion (PNI) have been identified as prognostic markers yet are not part of TNM classification. The aim of this study is to determine the prognostic importance of these factors and overall survival in patients with oesophageal or junctional cancer who underwent transthoracic oesophagectomy as the unimodality treatment. METHODS: Data from patients who underwent transthoracic oesophagectomy for adenocarcinoma without neoadjuvant treatment were reviewed. Patients were treated with radical resection, with a curative intent using a transthoracic Ivor Lewis or three staged McKeown approach. RESULTS: A total of 172 patients were included. Survival was poorer when VI, LI and PNI were present (p<0.001), with the estimated survival being significantly worse (p<0.001) when patients were stratified according to the number of factors present. Univariable analysis of factors revealed VI, LI and PNI were all associated with survival. Presence of LI was independently predictive of incorrect staging/upstaging in multivariable logistic regression analysis (OR 12.9 95% CI 3.6-46.6, p<0.001). CONCLUSION: Histological factors of VI, LI and PNI are markers of aggressive disease and may have a role in prognostication and decision-making prior to treatment. The presence of LI as an independent marker of upstaging could be a potential indication for the use of neoadjuvant treatment in patients with early clinical disease.
目的:食管癌的预后主要基于疾病的TNM分期。然而,即使在TNM分期相似的患者中,生存率也可能有所不同。其他组织病理学因素,包括静脉侵犯(VI)、淋巴侵犯(LI)和神经周围侵犯(PNI),已被确定为预后标志物,但并非TNM分类的一部分。本研究的目的是确定这些因素以及接受经胸食管切除术作为单一治疗方式的食管或交界性癌患者的总生存率的预后重要性。 方法:回顾了接受经胸食管切除术治疗腺癌且未接受新辅助治疗的患者的数据。患者接受根治性切除,采用经胸Ivor Lewis或三阶段McKeown方法,以达到治愈目的。 结果:共纳入172例患者。存在VI、LI和PNI时生存率较差(p<0.001),根据存在的因素数量对患者进行分层时,估计生存率明显更差(p<0.001)。对因素的单变量分析显示,VI、LI和PNI均与生存率相关。在多变量逻辑回归分析中,LI的存在独立预测分期错误/分期上调(OR 12.9,95%CI 3.6 - 46.6,p<0.001)。 结论:VI、LI和PNI的组织学因素是侵袭性疾病的标志物,可能在预后评估和治疗前的决策中发挥作用。LI作为分期上调的独立标志物的存在可能是早期临床疾病患者使用新辅助治疗的潜在指征。
Langenbecks Arch Surg. 2023-5-9
Eur J Cardiothorac Surg. 2019-5-1
N Engl J Med. 2021-4-1
Br J Surg. 2021-6-22
Endosc Int Open. 2021-3
J Thorac Dis. 2019-8